Scott T. Tagawa, MD, on Clinical Implications of Using an Anti-PSMA Antibody With Ketoconazole, Hydrocortisone, and Lutetium-177 in Treatment of Prostate Cancer

Posted: Wednesday, March 8, 2023

Scott T. Tagawa, MD, of Weill Cornell Medicine, NewYork-Presbyterian Hospital, discusses practical clinical questions raised by phase II findings showing that the anti-PSMA (prostate-specific membrane antibody) monoclonal antibody J591, when combined with ketoconazole and hydrocortisone and radiolabeled with lutetium-177 (vs. indium-111), may lead to improved 18-month metastasis-free survival for patients with high-risk, low-volume prostate cancer. This supports the development of anti-PSMA radioimmunotherapy, though the optimal radionuclide and targeting agent are still unknown.

---